Longer survival seen with Amgen's Kyprolis vs Velcade in myeloma study
February 28, 2017 at 09:01 AM EST
Feb 28 (Reuters) - Patients with relapsed multiple myeloma treated with Amgen Inc's Kyprolis lived more than seven months longer than those who received Takeda Pharmaceutical Co's Velcade, according to data from a late-stage study released by Amgen on Tuesday.
